Intestinal Microbiota: Novel Personalized Cancer Immunotherapy in Colorectal Cancer Publisher Pubmed



Azimi M¹ ; Keshavarz Shahbaz S² ; Mansourabadi AH^{3, 4, 5} ; Mohamed Khosroshahi L³ ; Pourkalhor S⁶ ; Rezakhani M^{6, 7} ; Masoumi F⁶ Show Affiliations
Source: International Archives of Allergy and Immunology Published:2022

Abstract

The human colon harbors a diverse array of microorganisms that play fundamental roles in colorectal cancer (CRC). Increasing evidence indicates that dysbiosis of the intestinal microbiome has been associated with the development of CRC. Interaction between host genetics, intestinal microbiota, and lifestyle is well-indicated in the influence, prevention, and treatment of CRC. Various microbiome compositions have reported anticancer and/or anti-inflammatory properties. The presence of our microbiota is integral to our development, but a change in its composition can often lead to adverse effects, increasing the propensity for serious diseases like cancers. Recently, molecular detection and metabolomic techniques have increased our knowledge of the role of microbiota in promoting tumorigenesis. Dietary interventions may be appropriate to regulate the growth of beneficial microbiota in the gut. Metagenomic approaches along with immunology and metabolomics will obvious a new path for the treatment of CRC. In this study, we summarized recent advances in understanding the mechanisms involved in microbiota-related colorectal carcinoma, based on evidence from immunotherapy studies. © 2022 S. Karger AG, Basel. Copyright: All rights reserved.